NasdaqGS:CRNXPharmaceuticals
Crinetics Pharmaceuticals (CRNX) Is Up 6.9% After Promising Phase 2 Atumelnant And Paltusotine Data Release - Has The Bull Case Changed?
Crinetics Pharmaceuticals recently presented Phase 2 TouCAHn data showing atumelnant reduced glucocorticoid doses while maintaining androgen control in classic congenital adrenal hyperplasia, and shared two-year PALSONIFY (paltusotine) data in acromegaly indicating maintained disease control and tolerability, while also scheduling its second-quarter 2026 earnings release and business update call for August 4, 2026.
Together, these clinical updates highlight Crinetics’ progress in rare...